HSK21542 is a peripherally-restricted kappa opioid receptor (KOR) agonist developed for pain treatment. Because of the CNS pharmacological concern of opioid receptor activation, such as physical dependence and addiction potential, an assessment of abuse potential of HSK21542 was required prior to marketing approval. The preclinical abuse potential assessments for HSK21542 included the following studies: 1) intravenous self-administration study to explore the relative reinforcing efficacy in rats self-administering remifentanil; 2) rat drug discrimination study to examine the pharmacological similarity of the interoceptive or subjective effects of HSK21542 in rats discriminating pentazocine; 3) rat conditioned place preference (CPP) paradigm to test the rewarding effects; 4) rat natural physical dependence-spontaneous withdrawal study in rats chronically treated with HSK21542; 5) naloxone-precipitated withdrawal assay following chronic HSK21542 exposure to evaluate its physical dependence potential. The results showed that HSK21542 was devoid of behavioral evidence of positive reinforcing effect and did not share similar discriminative stimulus effects with pentazocine. HSK21542 also did not produce CPP in rats. In addition, HSK21542 did not produce spontaneous withdrawal or naloxone-precipitated withdrawal in rats with chronic treatments. Collectively, these preclinical findings suggest that HSK21542 has no abuse potential in animals, which demonstrate low abuse potential in humans.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yrtph.2024.105731 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics.
Sci Rep
December 2024
Department of Pharmacology, University of the Basque Country, UPV/EHU, Sarriena S/N, 48940, Leioa, Bizkaia, Spain.
Cannabis use disorder affects up to 42% of individuals with schizophrenia, correlating with earlier onset, increased positive symptoms, and more frequent hospitalizations. This study employed an untargeted lipidomics approach to identify biomarkers in plasma samples from subjects with schizophrenia, cannabis use disorder, or both (dual diagnosis), aiming to elucidate the metabolic underpinnings of cannabis abuse and schizophrenia development. The use of liquid chromatography-high resolution mass spectrometry enabled the annotation of 119 metabolites, with the highest identification confidence level achieved for 16 compounds.
View Article and Find Full Text PDFMDMA as well as amphetamine and alcohol increase feelings of social closeness in healthy adults.
Sci Rep
December 2024
Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
Psychoactive drugs such as alcohol and stimulants are typically used in social settings such as bars, parties or small groups. Yet, relatively little is known about how social contexts affect responses to drugs, or how the drugs alter social interactions. It is possible that positive social contexts enhance the rewarding properties of drugs, perhaps increasing their potential for repeated use and abuse.
View Article and Find Full Text PDFMeasuring technology-facilitated sexual violence and abuse: a scoping review protocol of existing measurements.
BMJ Open
December 2024
School of Nursing and Midwifery, University of Birmingham, Birmingham, UK.
Introduction: Technology-facilitated sexual violence and abuse (TFSVA) refers to a range of behaviours in which digital technologies are used to facilitate both virtual and face-to-face sexual harm. The proliferation of smartphone usage and increasing internet penetration rates across the world have made it easier for individuals to become perpetrators and victims of TFSVA. Since empirical studies of TFSVA remain limited in the academic arena, and there is an absence of evidence to support the development of a standardised TFSVA measurement, this review aims to explore what TFSVA measurements are currently available and their potential use in measuring TFSVA.
View Article and Find Full Text PDFChemistry to cognition: Therapeutic potential of (m-CF-PhSe) targeting rats' striatum dopamine proteins in amphetamine dependence.
Prog Neuropsychopharmacol Biol Psychiatry
December 2024
Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas (LaftamBio Pampa), Universidade Federal do Pampa, Itaqui, RS, Brazil. Electronic address:
Amphetamine (AMPH) abuse represents a major global public health issue, highlighting the urgent need for effective therapeutic interventions to manage addiction caused by this psychostimulant. This study aimed to assess the potential of m-trifluoromethyl-diphenyldiselenide [(m-CF-PhSe)] in preventing the addictive effects induced by AMPH through targeting dopamine metabolism proteins. (m-CF-PhSe) is of interest due to its demonstrated efficacy in mitigating opioid abuse, establishing it as a promising candidate for addiction treatment research.
View Article and Find Full Text PDFEffect of serotonin receptor gene variants on substance use disorders.
Ann Med
December 2025
Department of Anatomy, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Background: Substance use disorders are multifaceted conditions influenced by both genetic and environmental factors. Serotonergic pathways are known to be involved in substance use disorder susceptibility, with genetic markers within serotonin receptor genes identified as potential risk factors.
Methods: To further explore this relationship, we conducted a study to investigate the association between several polymorphisms in five serotonin receptor genes (, , ) and substance use disorders (SUD) in Jordanian males by sequencing genotypes in 496 SUD patients and 496 healthy controls.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!